

PROVIDER QUICK POINTS

PROVIDER INFORMATION



August 9, 2023

Commercial Pharmacy Benefit Exclusion for Elevidys, Rystiggo®, and Vyvgart® Hytrulo

Effective **August 9, 2023**, the drugs listed in the table below will be excluded from pharmacy benefit coverage due to clinician-administered route of administration and may be available for medical benefit coverage for subscribers who are eligible.

Drug Names
Elevidys (delandistrogene moxeparvovec-rokl) solution for intravenous (IV) infusion
Rystiggo® (rozanolixizumab-noli) solution for subcutaneous (SC) infusion
Vyvgart® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) solution for subcutaneous (SC) infusion

Products Impacted

These exclusions apply to commercial lines of business.

Questions?

Please contact provider services at **(651) 662-5200** or **1-800-262-0820**.